GlassScriptPhysician profile
Roman Zuckerman
NPI 1639563927
$5,708.37
in general payments reported to CMS, 2019-2025
23 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $161 · 2021: $717 · 2022: $1,178 · 2023: $366 · 2024: $1,017 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.81 |
| Education | $157.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,805.58 | 2020-2025 | Evenity, Tavneos, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $641.65 | 2019-2025 | Orencia |
| Abbvie INC. | $577.98 | 2020-2024 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $459.34 | 2024-2025 | Tremfya |
| Glaxosmithkline, LLC. | $331.69 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $311.28 | 2024-2025 | |
| Pfizer INC. | $295.39 | 2021-2025 | |
| Ucb, INC. | $224.12 | 2022-2025 | Bimzelx |
| Horizon Therapeutics Plc | $170.03 | 2021-2022 | |
| Lilly USA, LLC | $167.55 | 2022-2024 | Taltz |
| Genentech USA, INC. | $163.75 | 2019-2025 | Actemra, Ocrevus Zunovo, Gazyva |
| Aurinia Pharma U.S., INC. | $120.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $76.94 | 2021-2025 | |
| Sobi, INC | $59.81 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $51.51 | 2025 | |
| Organon LLC | $34.45 | 2023-2025 | Hadlima, Renflexis |
| Azurity Pharmaceuticals, INC. | $29.11 | 2023 | Horizant |
| Hikma Pharmaceuticals USA | $27.91 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $16.89 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2022 | |
| Fidia Pharma USA INC. | $14.72 | 2025 | Hymovis, Triluron |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.